keynote-426 - pembrolizumab plus axitinib versus sunitinib for mrcc
Published 4 years ago • 440 plays • Length 4:47Download video MP4
Download video MP3
Similar videos
-
2:06
updated analysis of keynote-426: pembro plus axitinib vs sunitinib in mrcc
-
3:10
keynote-426 rationale and results: pembro plus axitinib vs. sunitinib in mrcc
-
1:45
keynote-426: pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma
-
6:58
keynote-426 study
-
2:18
pembrolizumab monotherapy and pembro-axitinib for rcc
-
2:31
axitinib plus pembrolizumab in advanced rcc
-
3:28
dr rini on a biomarker analysis for pembrolizumab/axitinib in advanced rcc
-
0:58
michael atkins, md, regarding the keynote 426 phase iii trial in metastatic renal cell carcinoma
-
2:23
overview of a phase iii trial of pembrolizumab plus axitinib in rcc
-
1:00
pembrolizumab/axitinib and avelumab/axitinib combo for rcc
-
1:44
renal cancer highlights from 2019 gu: keynote-426
-
1:46
researcher comment: updated keynote-426 data | elizabeth plimack
-
3:30
promising results for axitinib and pembrolizumab in advanced renal cell cancer
-
1:04
tian zhang, md, elaborates on the outcomes of keynote 426 presented at gu 2019
-
1:33
dr. powles on the results of the keynote-426 trial in mrcc
-
4:49
pembrolizumab plus axitinib and the future of further-line mrcc treatments
-
5:10
real-world treatment outcomes of 1l axitinib pembrolizumab in patients with advanced rcc in the us
-
0:44
rana mckay, md, elaborates on the outcomes of the keynote 426 phase iii study in mrcc
-
1:04
dr. rini discusses pembrolizumab plus axitinib in mrcc